Prevention of HPV-related cancers in Norway: Cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Burger, Emily A ^a   Sy, Stephen ^b   Nygar̊d, Mari ^c   Kristiansen, Ivar S ^a   Kim, Jane J ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c CANCER REGISTRY OF NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ANUS CANCER; ARTICLE; CANCER PREVENTION; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; MALE; NORWAY; OROPHARYNX CANCER; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PENIS CANCER; QUALITY ADJUSTED LIFE YEAR; SEX DIFFERENCE; UTERINE CERVIX CANCER; VAGINA CANCER; VIRUS TRANSMISSION; VULVA CANCER; WART VIRUS; ADOLESCENT; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; UROGENITAL NEOPLASMS; VACCINATION; VIROLOGY;

ADOLESCENT; COST-BENEFIT ANALYSIS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MALE; NORWAY; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SENSITIVITY AND SPECIFICITY; UROGENITAL NEOPLASMS; VACCINATION;

EID: 84911499519     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089974     Document Type: Article

References (51)

1. Norwegian Institute of Public Health (2012) [Annual Report for HPV-vaccine in the childhood vaccination program 2012]. Available: http://www.fhi.no/dokumenter/7ff40bd3b6.pdf. Accessed 2013 Aug 6.
2. David B (2013) Australia launches national scheme to vaccinate boys against HPV. BMJ 346: f924.
3. Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC (2011) Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd Immunity. Journal of Infectious Diseases 204: 372-376.
4. Ali H, Donovan B, Wand H, Read TRH, Regan DG, et al. (2013) Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 346: f2032.
5. Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, et al. (2013) Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. Journal of Infectious Diseases 208: 385-393.
6. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE (2011) The cost-effectiveness of male HPV vaccination in the United States. Vaccine 29: 8443-8450.
7. Kim JJ, Goldie SJ (2009) Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 339: b3884.
8. Mark J, Yoon HC, Edmunds WJ (2008) Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337: a769.
9. Farmastat AS website. Available: http://www.farmastat.no. Accessed 2013 May 3
10. Schiller JT, Castellsague X, Garland SM (2012) A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines. Vaccine 30: F123-F138.
11. Dobson SRM, McNeil S, Dionne M, Dawar M, Ogilvie G, et al. (2013) Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women A Randomized Clinical Trial. Jama-Journal of the American Medical Association 309: 1793-1802.
12. Norwegian Ministry of Health [Prioritising for new: Revision of guidelines for priority-setting within Norwegian Health]. Available: http://www.regjeringen.no/Rpub/NOU/19971997/018/PDFA/NOU199719970018000DDDPDFA. pdf. Accessed 2013 June 30.
13. Kim JJ, Goldie SJ (2008) Health and economic implications of HPV vaccination in the United States. New England Journal of Medicine 359: 821-832.
14. Federal Reserve. Historical Rates for the Norwegian Krone. Available: http://www.federalreserve.gov/RELEASES/H10/Hist/dat00-no.htm. Accessed 2011 Jun 13.
15. Norwegian Directorate of Health (2012) [Economic Evaluation of Healthcare - A Guide] Available: http://helsedirektoratet.no/publikasjoner/okonomisk- evaluering-av-helsetiltak-en-veileder/Publikasjoner/IS-1985.pdf. Accessed 2013 Jan 15
16. Norwegian Directorate of Health [Health Effects of Socio-Economic Analyses] (2007) Available: http://www.helsedirektoratet.no/publikasjoner/ helseeffekteri-samfunnsokonomiske-analyser/Publikasjoner/helseeffekter-i- samfunnsokonomiske-analyser.pdf.Accessed 2011 Jan 6.
17. Burger EA, Ortendahl JD, Sy S, Kristiansen IS, Kim JJ (2012) Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br J Cancer 106: 1571-1578.
18. Pedersen W, Samuelsen SW (2003) [New patterns of sexual behavior among adolescents]. Journal of the Norwegian Medical Society (Tidsskrift for Den norske legeforening) 21: 3006-3009.
19. Træen B, Stigum H, Magnus P (2003) [Report from the sexual behavior survey in 1987, 1992, 1997, 2002]. Norwegian Institute for Public Health, Division of Epidemiology.
20. Hernandez BY, Wilkens LR, Zhu X, Thompson P, McDuffie K, et al. (2008) Transmission of human papillomavirus in heterosexual couples. Emerging Infectious Diseases 14: 888-894. (Pubitemid 351838596)
21. Cancer Registry of Norway: Institute of population-based cancer research. http://www.kreftregisteret.no.
22. Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, et al. (2007) Multiparameter calibration of a natural history model of cervical cancer. American Journal of Epidemiology 166: 137-150. (Pubitemid 47227293)
23. World Health Organization. ICO (Institut Català d'Oncologia). Information Centre on Human Papilloma Virus (HPV) and Cervical Cancer: Data Query System. Available: http://www.who.int/hpvcentre/en/. Accessed 2012 Nov 15.
24. Mork J (2012) Prevalence of HPV in oropharyngeal carcinomas in patients diagnosed at Oslo University Hospital 2010-1011 [conference proceeding]. MD Anderson GAP Conference 2012. Available: http://webtv.medinfo.no/Mediasite/Play/ 99a9cb5b7412477c8a92e0413db5321b1d?catalog=54190625-deb6-433e-869c-b4fbf3b58b6c. Accessed 2013 Feb 2.
25. Myers E, Green S, Lipkus I (2004) Patient preferences for health states related to HPV infection: visual analygue scales versus time trade-off eliciation [abstract]. Proceeding of the 21st International Papillomavirus Conference. Mexico City, Mexico.
26. Conway EL, Farmer KC, Lynch WJ, Rees GL, Wain G, et al. (2012) Quality of life valuations of HPV-associated cancer health states by the general population. Sexually Transmitted Infections 88: 517-521.
27. Rannestad T, Skjeldestad FE (2008) Long-term survivors of gynaecological cancer are like other women in terms of pain and quality of life (QoL). Psychology & Health 23: 219.
28. Klee M, Thranov I, Machin D (2000) The patients' perspective on physical symptoms after radiotherapy for cervical cancer. Gynecologic Oncology 76: 14-23. (Pubitemid 30048313)
29. Olsen J, Jepsen MR (2010) Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. International Journal of Technology Assessment in Health Care 26: 183-191.
30. Bishai D, Kashima H, Shah K (2000) The cost of juvenile-onset recurrent respiratory papillomatosis. Archives of Otolaryngology-Head & Neck Surgery 126: 935-939. (Pubitemid 30658290)
31. Woodhall SC, Jit M, Soldan K, Kinghorn G, Gilson R, et al. (2011) The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK. Sexually Transmitted Infections 87: 458-463.
32. Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, et al. (2013) Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. International Journal of Cancer 132: 854-867.
33. Leval A, Herweijer E, Ploner A, Eloranta S, Fridman Simard J, et al. (2013) Quadrivalent Human Papillomavirus Vaccine Effectiveness: A Swedish National Cohort Study. Jnci-Journal of the National Cancer Institute 105: 469-474.
34. Health Protection Agency. Number & rates of anogenital warts diagnosed in England, 2002-2011.Available: http://www.hpa.org.uk/webc/ HPAwebFile/HPAweb-C/1296688631209. Accessed 2013 Jan 11.
35. Lacey CJN, Lowndes CM, Shah KV (2006) Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24: 35-41.
36. Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH (1999) Detection of multiple human papillomavirus types in condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. Journal of Clinical Microbiology 37: 3316-3322. (Pubitemid 29455226)
37. Omland T, Akre H, Vardal M, Brondbo K (2012) Epidemiological aspects of recurrent respiratory papillomatosis: A population-based study. Laryngoscope 122: 1595-1599.
38. Cancer Registry of Norway (2009) Cancer in Norway 2009. Special Issue: Cancer screening in Norway. Available: http://www.kreftregisteret.no/Global/ Publikasjoner%20og%20ra-pporter/Special%20Issue/Special-Issue-Cancer-in-Norway- 2009.pdf. Accessed 2011 Jan 6.
39. Norwegian Medicines Agency (2010) [Pharmaceutical assessment: Ipilimumab (Yervoy) for treatment of advanced malignant melanoma in adults with previous treatment]. Available: http://www.legemiddelverket.no/English/Sider/default. aspx. Accessed 2013 Jun 16.
40. Elbasha EH, Dasbach EJ (2010) Impact of vaccinating boys and men against HPV in the United States. Vaccine 28: 6858-6867.
41. Taira AV, Neukermans CP, Sanders GD (2004) Evaluating human papillomavirus vaccination programs. Emerging Infectious Diseases 10: 1915-1923. (Pubitemid 39458555)
42. Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM (2007) Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: A transmission dynamic model-based evaluation. Vaccine 26: 128-139. (Pubitemid 350218187)
43. Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, et al. (2007) A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sexual Health 4: 165-175. (Pubitemid 47339645)
44. Zechmeister I, de Blasio BF, Garnett G, Neilson AR, Siebert U (2009) Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine 27: 5133-5141.
45. French KM, Barnabas RV, Lehtinen M, Kontula O, Pukkala E, et al. (2007) Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. British Journal of Cancer 96: 514-518. (Pubitemid 46215226)
46. Choi YH, Jit M, Gay N, Cox A, Garnett GP, Edmunds WJ (2010) Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine 28: 4091-4102.
47. Bogaards JA, Kretzschmar M, Xiridou M, Meijer CJLM, Berkhof J, et al. (2001) Sex-Specific Immunization for Sexually Transmitted Infections Such as Human Papillomavirus: Insights from Mathematical Models. Plos Medicine 8.
48. Seto K, Marra F, Raymakers A, Marra CA (2012) The Cost Effectiveness of Human Papillomavirus Vaccines A Systematic Review. Drugs 72: 715-743.
49. Mork J, Møller Br, Dahl T, Bray F (2010) Time trends in pharyngeal cancer incidence in Norway 1981-2005: a subsite analysis based on a reabstraction and recoding of registered cases. Cancer Causes and Control 21: 1397-1405.
50. Malagón T, Drolet M, Boily M, Franco EL, Jit M, et al. (2012) Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. The Lancet Infectious Diseases 12: 781-789.
51. Larsen TK, Småstuen M, Parkin DM, Bray F (2007) Data Quality at the Cancer Registry of Norway. In: Cancer in Norway 2006-Cancer incidence, mortality, survival and prevalence in Norway. Available: http://www. kreftregisteret.no/Global/Publikasjoner%20og%20rapporter/CiN2006-special-issue. pdf. Accessed 2013 Jul 7.